Sensei Biotherapeutics Inc SNSE
Set alert
13.85 USD 0.00 0.00%
At close · Jun 15
14.01 +0.16 +1.16%
After hours · Jun 15, 4:00 PM ET
13.76 Day range 16.52
0.384 52-week range 1.94
- YTD
- +29.80%
- 1 year
- +85.16%
- Open
- 15.21
- Prev close
- 13.85
- Mkt cap
- 11.37M
- Vol
- 219.47K
- Avg vol
- 460.67K
- EPS
- -1.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.76
- High
- 16.52
- Forward P/E
- -0.40
- Beta
- 0.06
- Short ratio
- 0.29
- Inst. own
- 8.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 0.5072
- 200-d avg
- 0.747255
- 1y target
- 4.13
2Y chart
Events in this range
- Aug 6, 2024Earnings: -0.28; estimate -0.25; surprise -12%
- Aug 6, 2024Earnings: —; estimate -0.25; surprise —%
- Aug 7, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 14, 2024Earnings: -0.29; estimate -0.31; surprise 6.45%
- Jun 17, 2025Split: 1 for 20
Signals (107)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| RSI: Oversold | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| RSI: Oversold | May 14, 2026 | 5 months ago |
| RSI: Oversold | May 11, 2026 | 5 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| RSI: Overbought | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Mar 4, 2026 | 8 months ago |
| SMA: Bullish | Feb 18, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| RSI: Overbought | Feb 18, 2026 | 8 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Dec 31, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 18, 2025 | 10 months ago |
| SMA: Bullish | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| SMA: Bullish | Dec 3, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
| SMA: Bearish | Nov 28, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bullish | Nov 19, 2025 | 11 months ago |
| SMA: Bullish | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 12, 2025 | 11 months ago |
| SMA: Bearish | Oct 28, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 21, 2025 | 1 year ago |
| RSI: Overbought | Oct 13, 2025 | 1 year ago |
| RSI: Overbought | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 9, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Sep 5, 2025 | 1 year ago |
| SMA: Bullish | Sep 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 3, 2025 | 1 year ago |
| SMA: Bearish | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 26, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Aug 21, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 8, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 1, 2025 | 1 year ago |
| RSI: Overbought | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jul 2, 2025 | 1 year ago |
| SMA: Bullish | Jun 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| SMA: Bearish | Apr 16, 2025 | 1 year ago |
| SMA: Bullish | Apr 15, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 2, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 5, 2024 | 1 year ago |
| SMA: Bearish | Dec 3, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 22, 2024 | 1 year ago |
| SMA: Bearish | Nov 14, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 13, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 12, 2024 | 1 year ago |
| SMA: Bullish | Nov 7, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 1, 2024 | 2 years ago |
| SMA: Bearish | Oct 31, 2024 | 2 years ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 21, 2024 | 2 years ago |
| RSI: Overbought | Oct 21, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 8, 2024 | 2 years ago |
| SMA: Bearish | Oct 1, 2024 | 2 years ago |
| SMA: Bullish | Sep 30, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 24, 2024 | 2 years ago |
Key statistics
- Market cap
- 11.37M
- Enterprise value
- -35.62M
- Trailing P/E
- 0.00
- Forward P/E
- -0.40
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.17
- EPS (TTM)
- -1.19
- Beta
- 0.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -14.90M
- Total cash
- 52.29M
- Total debt
- 5.05M
- Return on equity
- -45.17%
- Shares outstanding
- 25.15M
- Short % of float
- 1.16%
- 50-day average
- 0.5072
- 200-day average
- 0.747255
Analyst view
Consensus: none
Price target (mean) 4.13 -70.2% downside
Now 13.85
- Target (low)
- 3.50
- Target (mean)
- 4.13
- Target (high)
- 5.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.29984.
Financials — quick view
SNSE Revenue — quarterly 0
SNSE Net income — quarterly -170.24M
SNSE EPS — quarterly -131.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.31 | -0.29 | +0.02 | +6.45% |
| Aug 6, 2024 | Jun 1, 2024 | -0.25 | -0.28 | -0.03 | -12.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.25 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.29 | -0.32 | -0.03 | -10.34% |
| May 9, 2024 | Mar 1, 2024 | -0.29 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.32 | -0.30 | +0.02 | +6.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 24, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| May 14, 2024 | Stephens & Co. | init | — | Overweight |
| Dec 4, 2023 | HC Wainwright & Co. | init | — | Buy |
| Dec 13, 2022 | Citigroup | init | — | Buy |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- senseibio.com
News
- Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
- This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
- This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- This Daktronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on SNSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRODER SAMUEL | Director | Stock Award(Grant) | Jul 9, 2023 | 8,932 |
| CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 9, 2023 | 5,240,420 |
| CELEBI JOHN | Chief Executive Officer | Purchase | Sep 10, 2023 | 111,311 |
| ENGLISH JESSIE | Director | Stock Award(Grant) | Jul 9, 2023 | 8,932 |
| HOLMEN BOB | Director | Stock Award(Grant) | Jul 9, 2023 | 25,598 |
| HUMER KRISTIAN | Director | Stock Award(Grant) | Jul 9, 2023 | 8,932 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 2.58% | 650,000 | 293.80K | Sep 29, 2024 |
| Vanguard Group Inc | 2.46% | 618,757 | 279.68K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.86% | 215,572 | 97.44K | Sep 29, 2024 |
| Boothbay Fund Management, LLC | 0.69% | 172,835 | 78.12K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.65% | 163,139 | 73.74K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.36% | 90,428 | 40.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.93% | 485,960 | 219.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.40% | 99,616 | 45.03K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 90,441 | 40.88K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.19% | 47,900 | 21.65K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 28,330 | 12.80K | Oct 30, 2024 |
| Vanguard Balanced Index Fund | 0.07% | 18,109 | 8.19K | Sep 29, 2024 |